FONAR CORPORATION (FONR)
Healthcare › Electromedical & Electrotherapeutic Apparatus
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 25% below Graham Number ($24.76) — significant margin of safety
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 7.4% — below-average profitability
FONAR CORPORATION (FONR) is a Healthcare company operating in Electromedical & Electrotherapeutic Apparatus, listed on the NASDAQ , with a market capitalisation of $127 million . Key value metrics: P/E ratio 14.5, P/B ratio 0.72, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
FONAR CORPORATION — Fundamental Analysis Summary
FONAR CORPORATION (FONR) is trading 25% below its Graham Number of $24.76 — a significant margin of safety by Benjamin Graham's standard. The stock carries a reasonable trailing P/E ratio of 14.5x.
On financial health, FONR shows a moderate Piotroski F-Score of 5/9, and modest return on equity of 7.4% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.01.
StockPik's composite Value Score for FONR is 72/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
FONR shows revenue growing at 1% year-over-year, with earnings declining at 21%.